The mitomycin C HAP porfiromycin [50] and the irreversible EGFR inhibitor HAP tarloxotinib have also failed to show benefit in HNSCC clinical trials, although the failure of tarloxotinib may reflect not only a lack of biomarker support but the challenges of assessing HAPs as monotherapy when they are only targeting a subset of the tumour microenvironment. This evidence concerns the gene EGFR and neoplasm.